XBiotech Inc. (XBIT): Price and Financial Metrics


XBiotech Inc. (XBIT): $5.59

0.15 (+2.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XBIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XBIT POWR Grades


  • Value is the dimension where XBIT ranks best; there it ranks ahead of 93.39% of US stocks.
  • The strongest trend for XBIT is in Value, which has been heading up over the past 179 days.
  • XBIT's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

XBIT Stock Summary

  • For XBIT, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • XBIT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.55% of US stocks.
  • As for revenue growth, note that XBIT's revenue has grown -58.19% over the past 12 months; that beats the revenue growth of only 2.6% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to XBiotech Inc are BPMC, KLDO, APTX, IDYA, and CALA.
  • Visit XBIT's SEC page to see the company's official filings. To visit the company's web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • XBIT's price/sales ratio is 19.3; this is 70.04% higher than that of the median Healthcare stock.
  • XBIT's price/sales ratio has moved NA NA over the prior 78 months.
  • Over the past 78 months, XBIT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2021-08-31 19.3 1.4 -40.3 -9.4
XBIT 2021-08-30 19.5 1.4 -40.9 -9.8
XBIT 2021-08-27 19.4 1.4 -40.7 -9.7
XBIT 2021-08-26 19.2 1.4 -40.2 -9.4
XBIT 2021-08-25 19.1 1.4 -39.9 -9.2
XBIT 2021-08-24 19.2 1.4 -40.1 -9.3

XBIT Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -84.64%.
  • The 2 year cash and equivalents growth rate now stands at 750.01%.
  • Its 2 year net cashflow from operations growth rate is now at -193.92%.
Over the past 34 months, XBIT's revenue has gone up $18,394,000.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 18.394 69.445 -17.414
2021-09-30 19.163 70.813 -12.785
2021-06-30 25.193 81.698 -12.05
2021-03-31 36.166 -2.667 -13.776
2020-12-31 43.997 -65.149 -11.221
2020-09-30 38.728 -68.504 677.111

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBIT Stock Price Chart Interactive Chart >

Price chart for XBIT

XBIT Price/Volume Stats

Current price $5.59 52-week high $18.46
Prev. close $5.44 52-week low $5.36
Day low $5.37 Volume 57,400
Day high $5.62 Avg. volume 75,772
50-day MA $7.66 Dividend yield N/A
200-day MA $11.36 Market Cap 170.15M

XBiotech Inc. (XBIT) Company Bio


XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.


XBIT Latest News Stream


Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream


Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & JohnsonAUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech in December 2019. XBiotech discovers and develops therap

Yahoo | February 2, 2022

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) enrolled the first patient in a randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ. Natrunix-SQ targets a crucial inflammatory pathway involved in pain and joint destruction in various forms of arthritis. XBiotech be

Yahoo | January 26, 2022

Moderna CEO talks Omicron booster shots, 2022 COVID-19 vaccine sales forecasts, global vaccination

Moderna CEO Stéphane Bancel joins Yahoo Finance’s Anjalee Khemlani to discuss the development of an Omicron-specific booster shot, global vaccination efforts, data on the effectiveness of the COVID-19 vaccine, and raised forecasts for vaccine sales and production in 2022.

Yahoo | January 10, 2022

New COVID-19 vaccine that covers Omicron ‘will be ready in March,’ Pfizer CEO says

Pfizer CEO Albert Bourla joins Yahoo Finance’s Anjalee Khemlani to discuss the development of a new COVID-19 vaccine that will include protection against Omicron, vaccine production, and the outlook for an Omicron-specific booster.

Yahoo | January 10, 2022

Do Insiders Own Lots Of Shares In XBiotech Inc. (NASDAQ:XBIT)?

A look at the shareholders of XBiotech Inc. ( NASDAQ:XBIT ) can tell us which group is most powerful. Large companies...

Yahoo | December 15, 2021

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -33.69%
3-mo -43.31%
6-mo -54.85%
1-year -67.59%
3-year -36.26%
5-year -28.52%
YTD -49.78%
2021 -28.88%
2020 -16.15%
2019 267.42%
2018 28.93%
2017 -61.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4952 seconds.